The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Among women with gestational diabetes, the use of real-time continuous glucose monitoring (rt-CGM) is associated with a lower incidence of large-for-gestational-age (LGA) infants and reduced ...

Withdrawal of tirzepatide treatment in adults with obesity who have achieved initial weight loss is associated with substantial weight regain and a corresponding reversal of the positive ...

Topline data were announced from a phase 3 trial evaluating ersodetug in patients aged 3 months to 45 years with congenital hyperinsulinism.

Higher body dissatisfaction was linked to more severe eating disorder, depressive symptoms in monozygotic and dizygotic twin difference analyses. HealthDay News — Body dissatisfaction may causally ...

Second-generation automated insulin delivery (AID) systems improve glycemic control and treatment satisfaction in type 1 diabetes.

The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

A data monitoring committee recommended stopping the phase 3 trials of efgartigimod in thyroid eye disease due to lack of efficacy.

Giredestrant shows significant improvement in iDFS in patients with early-stage, HR-positive, HER2-negative breast cancer.